Organon & Co. (BMV:OGN)

Market Cap	35.34B -57.5%
Revenue (ttm)	115.57B -1.7%
Net Income	9.19B -61.5%
EPS	35.07 -62.1%
Shares Out	n/a
PE Ratio	3.85
Forward PE	2.20
Dividend	6.83 (4.29%)
Ex-Dividend Date	Nov 20, 2025

Volume	n/a
Average Volume	1,186
Open	159.04
Previous Close	159.04
Day's Range	159.04 - 159.04
52-Week Range	117.00 - 327.00
Beta	n/a
RSI	59.07
Earnings Date	Feb 12, 2026

About Organon & Co.

Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 10,000
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: OGN

Financial Performance

In 2024, Organon & Co.'s revenue was $6.40 billion, an increase of 2.24% compared to the previous year's $6.26 billion. Earnings were $864.00 million, a decrease of -15.54%.

Financial numbers in USD